Nurullah İlhan,MD· @drnurullahilhan · X·· 9 小时前评分70
正文 · 原文
INTerpath-001: personalized mRNA therapy meets its primary RFS endpoint in resected stage IIB–IV melanoma.
Intismeran + pembrolizumab vs placebo + pembrolizumab:
24-month RFS: 82.2% vs 70.0%
HR 0.58; P<0.001
DMFS also improved.
#INTerpath001 #ESMO2026 #Melanoma
5 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Nurullah İlhan,MD · x.com